Insider Selling: AstraZeneca (LON:AZN) Insider Sells 297 Shares of Stock

AstraZeneca PLC (LON:AZN) insider Nazneen Rahman sold 297 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of £134.96, for a total transaction of £40,083.12.

AstraZeneca Price Performance

AZN opened at £135.94 on Monday. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. AstraZeneca PLC has a 1-year low of GBX 9,573.51 and a 1-year high of £142.06. The company has a 50-day moving average of £132.20 and a 200-day moving average of £119.23. The company has a market capitalization of £210.75 billion, a P/E ratio of 22.58, a PEG ratio of 0.86 and a beta of 0.17.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 target price on shares of AstraZeneca in a research report on Thursday, December 4th. Shore Capital reissued a “buy” rating and set a £145 target price on shares of AstraZeneca in a research note on Thursday, November 6th. Berenberg Bank upped their price objective on shares of AstraZeneca from £142 to £145 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Finally, Jefferies Financial Group reissued a “buy” rating and issued a £150 target price on shares of AstraZeneca in a research report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of £138.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.